Skip to main content
. 2021 Dec 1;12:732135. doi: 10.3389/fimmu.2021.732135

Figure 4.

Figure 4

Bioreactors offer several advantages to the clinical manufacturing of cell therapies. The shift from static vessels on the left toward dynamic bioreactors on the right allows for several process improvements, such as scalability, automated and closed operation, digital integration, and intimate control of liquids. These capabilities result in increased safety and consistency, reduced labor requirement and cost, and improved quality of cellular output.